Azzani M, Roslani AC, Su TT. The perceived cancer-related financial hardship among patients and their families: a systematic review. Support Care Cancer 2015;23:889–898.
Miller KD, Siegel RL, Lin CC, et al.. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016;66:271–289.
Institute of Medicine. Ensuring Patient Access to Affordable Cancer Drugs: Workshop Summary. Washington, DC: National Academies Press; 2014.
Soni A. Trends in use and expenditures for cancer treatment among adults 18 and older, U.S. civilian noninstitutionalized population, 2001 and 2011. Statistical Brief #443. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
Dusetzina SB, Winn AN, Abel GA, et al.. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014;32:306–311.
Davidoff AJ, Erten M, Shaffer T, et al.. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer 2013;119:1257–1265.
Guy GP Jr, Ekwueme DU, Yabroff KR, et al.. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol 2013;31:3749–3757.
Yabroff KR, Lamont EB, Mariotto A, et al.. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630–641.
Short PF, Moran JR, Punekar R. Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer 2011;117:2791–2800.
Finkelstein EA, Tangka FK, Trogdon JG, et al.. The personal financial burden of cancer for the working-aged population. Am J Manag Care 2009;15:801–806.
Yabroff KR, Dowling EC, Guy GP Jr, et al.. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol 2016;34:259–267.
National Cancer Institute. Financial toxicity and cancer treatment (PDQ)—health professional version. Available at: https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-hp-pdq. Accessed February 14, 2018.
Altice CK, Banegas MP, Tucker-Seeley RD, et al.. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst 2016;109:djw205.
Ramsey S, Blough D, Kirchhoff A, et al.. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 2013;32:1143–1152.
Jagsi R, Ward KC, Abrahamse PH, et al.. Unmet need for clinician engagement about financial toxicity after diagnosis of breast cancer. Cancer 2018;124:3668–3676.
Shih YT, Chien CR. A review of cost communication in oncology: patient attitude, provider acceptance, and outcome assessment. Cancer 2017;123:928–939.
O’Connor JM, Kircher SM, de Souza JA. Financial toxicity in cancer care. J Community Support Oncol 2016;14:101–106.
Moher D, Liberati A, Tetzlaff J, et al.. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–269.
Meeker CR, Geynisman DM, Egleston BL, et al.. Relationships among financial distress, emotional distress, and overall distress in insured patients with cancer. J Oncol Pract 2016;12:e755–764.
Ryan R; Cochrane Consumers and Communication Review Group. Cochrane Consumers and Communication Review Group: data synthesis and analysis. Available at: http://cccrg.cochrane.org/sites/cccrg.cochrane.org/files/public/uploads/Analysis.pdf. Accessed May 9, 2019.
National Institutes of Health; National Heart, Lung, and Blood Institute. Study quality assessment tools. Available at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed February 14, 2018.
Whitney RL, Bell JF, Reed SC, et al.. Predictors of financial difficulties and work modifications among cancer survivors in the United States. J Cancer Surviv 2016;10:241–250.
Banegas MP, Guy GP Jr, de Moor JS, et al.. For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff (Millwood) 2016;35:54–61.
Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer 2016;122:283–289.
Pezzin LE, O’Niel MB, Nattinger AB. The economic consequences of breast cancer adjuvant hormonal treatments. J Gen Intern Med 2009;24(Suppl 2):S446–450.
Pisu M, Kenzik KM, Oster RA, et al.. Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer? Cancer 2015;121:1257–1264.
Bestvina CM, Zullig LL, Rushing C, et al.. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract 2014;10:162–167.
Zullig LL, Peppercorn JM, Schrag D, et al.. Financial distress, use of cost-coping strategies, and adherence to prescription medication among patients with cancer. J Oncol Pract 2013;9(Suppl 6):60s–63s.
The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Version 6. Available at: https://training.cochrane.org/handbook. Accessed May 9, 2019.
Veenstra CM, Regenbogen SE, Hawley ST, et al.. A composite measure of personal financial burden among patients with stage III colorectal cancer. Med Care 2014;52:957–962.
Shankaran V, Jolly S, Blough D, et al.. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol 2012;30:1608–1614.
Markman M, Luce R. Impact of the cost of cancer treatment: an internet-based survey. J Oncol Pract 2010;6:69–73.
Callahan C, Brintzenhofeszoc K. Financial quality of life for patients with cancer: an exploratory study. J Psychosoc Oncol 2015;33:377–394.
Fenn KM, Evans SB, McCorkle R, et al.. Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract 2014;10:332–338.
Jagsi R, Hawley ST, Abrahamse P, et al.. Impact of adjuvant chemotherapy on long-term employment of survivors of early-stage breast cancer. Cancer 2014;120:1854–1862.
Jagsi R, Pottow JAE, Griffith KA, et al.. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 2014;32:1269–1276.
Kircher SM, Johansen ME, Nimeiri HS, et al.. Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer. Cancer 2014;120:3378–3384.
Lathan CS, Cronin A, Tucker-Seeley R, et al.. Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. J Clin Oncol 2016;34:1732–1740.
Lee M, Khan MM. Gender differences in cost-related medication non-adherence among cancer survivors. J Cancer Surviv 2016;10:384–393.
Lee M, Salloum RG. Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors. J Cancer Surviv 2016;10:534–544.
Martin MY, Fouad MN, Oster RA, et al.. What do cancer patients worry about when making decisions about treatment? Variation across racial/ethnic groups. Support Care Cancer 2014;22:233–244.
Narang AK, Nicholas LH. Out-of-pocket spending and financial burden among Medicare beneficiaries with cancer. JAMA Oncol 2017;3:757–765.
Streeter SB, Schwartzberg L, Husain N, et al.. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. Am J Manag Care 2011;17(Suppl 5):SP38–44.
Tucker-Seeley RD, Abel GA, Uno H, et al.. Financial hardship and the intensity of medical care received near death. Psychooncology 2015;24:572–578.
Wan Y, Gao X, Mehta S, et al.. Indirect costs associated with metastatic breast cancer. J Med Econ 2013;16:1169–1178.
Abel GA, Albelda R, Khera N, et al.. Financial hardship and patient-reported outcomes after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2016;22:1504–1510.
Zafar SY, McNeil RB, Thomas CM, et al.. Population-based assessment of cancer survivors’ financial burden and quality of life: a prospective cohort study. J Oncol Pract 2015;11:145–150.
Regenbogen SE, Veenstra CM, Hawley ST, et al.. The personal financial burden of complications after colorectal cancer surgery. Cancer 2014;120:3074–3081.
Huntington SF, Weiss BM, Vogl DT, et al.. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol 2015;2:e408–416.
Chongpison Y, Hornbrook MC, Harris RB, et al.. Self-reported depression and perceived financial burden among long-term rectal cancer survivors. Psychooncology 2016;25:1350–1356.
de Souza JA, Yap BJ, Wroblewski K, et al.. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 2017;123:476–484.
Guy GP Jr, Yabroff KR, Ekwueme DU, et al.. Healthcare expenditure burden among non-elderly cancer survivors, 2008-2012. Am J Prev Med 2015;49(Suppl 5):S489–497.
Houts PS, Harvey HA, Simmonds MA, et al.. Characteristics of patients at risk for financial burden because of cancer and its treatment. J Psychosoc Oncol 1985;3:15–22.
Jones WC, Parry C, Devine S, et al.. Prevalence and predictors of distress in posttreatment adult leukemia and lymphoma survivors. J Psychosoc Oncol 2015;33:124–141.
Langa KM, Fendrick AM, Chernew ME, et al.. Out-of-pocket health-care expenditures among older Americans with cancer. Value Health 2004;7:186–194.
Pisu M, Azuero A, Benz R, et al.. Out-of-pocket costs and burden among rural breast cancer survivors. Cancer Med 2017;6:572–581.
Wong YN, Schluchter MD, Albrecht TL, et al.. Financial concerns about participation in clinical trials among patients with cancer. J Clin Oncol 2016;34:479–487.
Blinder V, Patil S, Eberle C, et al.. Early predictors of not returning to work in low-income breast cancer survivors: a 5-year longitudinal study. Breast Cancer Res Treat 2013;140:407–416.
Goodwin JA, Coleman EA, Sullivan E, et al.. Personal financial effects of multiple myeloma and its treatment. Cancer Nurs 2013;36:301–308.
Bernard DSM, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol 2011;29:2821–2826.
Ekwueme DU, Yabroff KR, Guy GP Jr, et al.. Medical costs and productivity losses of cancer survivors—United States, 2008–2011. MMWR Morb Mortal Wkly Rep 2014;63:505–510.
Khera N, Chang YH, Hashmi S, et al.. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20:1375–1381.
Meneses K, Azuero A, Hassey L, et al.. Does economic burden influence quality of life in breast cancer survivors? Gynecol Oncol 2012;124:437–443.
Francoeur RB. Cumulative financial stress and strain in palliative radiation outpatients: the role of age and disability. Acta Oncol 2005;44:369–381.
de Souza JA, Yap BJ, Hlubocky FJ, et al.. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 2014;120:3245–3253.
Kent EE, Forsythe LP, Yabroff KR, et al.. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 2013;119:3710–3717.
Meeker CR, Wong YN, Egleston BL, et al.. Distress and financial distress in adults with cancer: an age-based analysis. J Natl Compr Canc Netw 2017;15:1224–1233.
Neugut AI, Subar M, Wilde ET, et al.. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011;29:2534–2542.
Ramsey SD, Bansal A, Fedorenko CR, et al.. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 2016;34:980–986.
Zheng Z, Yabroff KR, Guy GP Jr, et al.. Annual medical expenditure and productivity loss among colorectal, female breast, and prostate cancer survivors in the United States. J Natl Cancer Inst 2015;108:djv382.
Wheeler SB, Spencer JC, Pinheiro LC, et al.. Financial impact of breast cancer in black versus white women. J Clin Oncol 2018;36:1695–1701.
Palmer NR, Weaver KE, Hauser SP, et al.. Disparities in barriers to follow-up care between African American and White breast cancer survivors. Support Care Cancer 2015;23:3201–3209.
Farias AJ, Hansen RN, Zeliadt SB, et al.. The association between out-of-pocket costs and adherence to adjuvant endocrine therapy among newly diagnosed breast cancer patients. Am J Clin Oncol 2018;41:708–715.
Ell K, Xie B, Wells A, et al.. Economic stress among low-income women with cancer: effects on quality of life. Cancer 2008;112:616–625.
Shankaran V, Leahy T, Steelquist J, et al.. Pilot feasibility study of an oncology financial navigation program. J Oncol Pract 2018;14:e122–129.
Farias AJ, Du XL. Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among Medicare patients with breast cancer. J Clin Oncol 2017;35:86–95.
Bender CM, Gentry AL, Brufsky AM, et al.. Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum 2014;41:274–285.
Zafar SY, Peppercorn JM, Schrag D, et al.. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 2013;18:381–390.
Nipp RD, Zullig LL, Samsa G, et al.. Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress. Psychooncology 2016;25:719–725.
DiMartino LD, Birken SA, Mayer DK. The relationship between cancer survivors’ socioeconomic status and reports of follow-up care discussions with providers. J Cancer Educ 2017;32:749–755.
Khera N, Chow EJ, Leisenring WM, et al.. Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 2011;17:995–1003.
Delgado-Guay M, Ferrer J, Rieber AG, et al.. Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients. Oncologist 2015;20:1092–1098.
Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231–2247.
Peng L, Ye X, Zhou Y, et al.. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Support Care Cancer 2015;23:2813–2824.
Peng L, Bu Z, Ye X, et al.. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care [Br] 2017;26:e12407.
Gordon LG, Merolini KMD, Lowe A, et al.. A systematic review of financial toxicity among cancer survivors: we can’t pay the co-pay. Patient 2017;10:295–309.
de Souza JA, Kung S, O’Connor J, et al.. Determinants of patient-centered financial stress in patients with locally advanced head and neck cancer. J Oncol Pract 2017;13:e310–318.
Gupta D, Lis CG, Grutsch JF. Perceived cancer-related financial difficulty: implications for patient satisfaction with quality of life in advanced cancer. Support Care Cancer 2007;15:1051–1056.